USA flag logo/image

An Official Website of the United States Government

PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2010 / STTR
Agency Tracking Number:
R42DK081298
Solicitation Year:
2010
Solicitation Topic Code:
NIDDK
Solicitation Number:
PA08-051
Small Business Information
METABOLIC SOLUTIONS DEVELOPMENT CO
125 KALAMAZOO MALL KALAMAZOO, MI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: PPAR-sparing/free Thiazolidinediones for Treatment of Diabetes
Agency: HHS
Contract: 4R42DK081298-02
Award Amount: $1,242,623.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall objective of our proposed research is to discover a PPARg-free thiazolidinedione (TZD) which shows antidiabetic activity in a rodent model of Type 2 diabetes and demonstrates the necessary drug-like qualities to become a clinical candidate for human therapeutics. The insulin sensitizing agents of the TZD class are conventionally thought to operate through binding to PPARg receptors. However, strong evidence has also been gathered to show that undesirable sideeffects of TZDs are mediated through PPARg binding. Moreover, it has recently been suggested that rosiglitazone, the prototypical PPARg activator, could have some untoward acute cardiovascular effects. Contrary to the prevailing scientific view, the investigators of this proposal believe that non-PPAR mediated mechanisms are responsible for the insulin sensitizing pharmacology. There is a critical need to challenge the status quo with the goal of finding com- pounds that might be useful in the treatment ofdiabetes. In this Fast Track STTR application, the Metabolic Solutions Development Company (MSD) proposes to build on its knowledge of PPARg-sparing TZDs and expand to a PPARg-free analog series; to evaluate the antidiabetic activity of the analogs in a rodent model of Type 2 diabetes; and to evaluate the drug-like properties (pharmacokinetics, bioavailability, preliminary toxicology) that are important in further clinical development. Our hypothesis is that the insulin sensitization occurs though mitochondrial effects of the TZDs at least partly through binding to a novel mitochondrial target protein, mitoNEET. Our academic collaborators at UCSD have further characterized mitoNEET as an Fe-S protein important to mitochondrial function. The current proposalwill transfer technology from UCSD to allow MSD to optimize PPARg-free analogs for treatment of Type 2 diabetes. The ultimate goal of this project is to identify a candidate PPAR3- free TZD that can be submitted to a STTR Phase III program which will require additional IND- driven preclinical evaluation. A successful candidate would then undergo clinical testing and would have the potential to be commercialized for treatment of Type 2 diabetes. PUBLIC HEALTH RELEVANCE: The incidence of type 2 diabetes is reaching epidemic proportions in our society. This proposal will provide insight into the mechanism of action of a major class of drugs used in the treatment of diabetes, called thiazolidinediones, which have undesirable side effects. It is the intent of the project to identify a new sub-class of thiazolidinediones for treatment of diabetes that are free of these undesirable side effects.

Principal Investigator:

Rolf F. Kletzien
304-293-2494
rkletzien@msdrx.com

Business Contact:

Rolf Kletxien
269-491-5690
rkletzien@msdrx.com
Small Business Information at Submission:

METABOLIC SOLUTIONS DEVELOPMENT CO
125 KALAMAZOO MALL KALAMAZOO, MI -

EIN/Tax ID: 120409983
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
University Of California San Diego
9500 GILMAN DR, DEPT 0934
LA JOLLA, CA 92093-0934
Contact: